Latest Conference Articles

November 5th 2021, 8:55pm

PER® New York Lung Cancer Symposium

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

November 5th 2021, 8:55pm

PER® New York Lung Cancer Symposium

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

November 5th 2021, 8:51pm

PER® New York Lung Cancer Symposium

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

November 5th 2021, 7:36pm

PER® Chemotherapy Foundation Symposium (CFS)

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

November 5th 2021, 7:03pm

PER® Chemotherapy Foundation Symposium (CFS)

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

November 5th 2021, 5:00pm

PER® New York Lung Cancer Symposium

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

November 5th 2021, 2:00pm

PER® New York Lung Cancer Symposium

Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.

November 4th 2021, 10:16pm

PER® Chemotherapy Foundation Symposium (CFS)

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

November 4th 2021, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.

November 4th 2021, 9:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.

November 4th 2021, 7:42pm

PER® Chemotherapy Foundation Symposium (CFS)

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

November 4th 2021, 7:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

November 4th 2021, 6:27pm

PER® Chemotherapy Foundation Symposium (CFS)

As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.

November 3rd 2021, 8:52pm

PER® Chemotherapy Foundation Symposium (CFS)

The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.

November 3rd 2021, 8:50pm

PER® Chemotherapy Foundation Symposium (CFS)

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

November 3rd 2021, 6:35pm

PER® Chemotherapy Foundation Symposium (CFS)

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

October 12th 2021, 7:56pm

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

September 23rd 2021, 2:00pm

ESMO Congress: Lung Cancer

The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.

September 22nd 2021, 7:00pm

ESMO Congress

Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.

September 22nd 2021, 3:10pm

International Workshop on CLL

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.